Cmt Prep Challenge #49

Front 1

This medication is prescribed as an adjunct to levodopa and carbidopa to treat symptoms of Parkinson disease. It is used only in patients with fluctuating symptoms that are not adequately controlled because of the risk of potentially fatal, acute fulminant liver failure. Black box guidelines in the prescribing information recommend that the patient undergo liver function tests before beginning treatment with this drug and that liver function be monitored regularly. The drug should be discontinued if symptoms do not improve within 3 weeks. In addition, if the drug is discontinued, it should not be restarted because there is an increased risk of liver injury. This medication is available as 100 mg and 200 mg film-coated tablets. The usual initial dosage is 100 mg 3 times daily. The dosage is then increased based on the patient's response. Many patients require a reduction in the dosage of their levodopa by as much as 30% when this medication is added to their regimen. Common side effects may include dyskinesia, nausea, and sleep disorders.
A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 1

A Tasmar (tolcapone)

Front 2

This recombinant human growth hormone is prescribed to treat children with growth failure and in adults with adult-onset growth hormone deficiency. It is available as 5.8 mg and 13.8 mg lyophilized powder that is mixed with sterile water for injection in a 2-cartridge GENOTROPIN MIXER™ Growth Hormone Reconstitution Device. It is also available as 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg doses that may be administered using the GENOTROPIN MINIQUICK device. The usual dosage range to treat growth hormone deficiency in children is 0.16 to 0.24 mg/kg per week. The dosage is divided into 6 or 7 subcutaneous injections per week. The initial dosage in adults is 0.04 mg/kg per week, which may be increased by 0.08 mg/kg per week every 4 to 8 weeks, or 0.2 mg/day, regardless of body weight, increased by 0.1 to 0.2 mg every 4 to 8 weeks. Adverse effects may include peripheral pain, stiffness, swelling/edema, paresthesia, muscle and joint pain.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 2

J Genotropin (Somatropin)

Front 3

This medication is indicated as replacement therapy in patients with hypothyroidism. It is also used as a TSH pituitary suppressant to treat or prevent goiters. This medication contains two forms of thyroid hormones: triiodothyronine (T3), and tetraiodothyronine (T4). It is available as tablets in five different T3/T4 potency combinations: 1/4 (3.1 mcg/12.5 mcg), 1/2 (6.25 mcg/25 mcg), 1 (12.5 mcg/50 mcg), 2 (25 mcg/100 mcg), and 3 (37.5 mcg/150 mcg). For thyroid replacement therapy in adults and children ages 12 years and older, the dosage is individualized to the patient, usually starting with the 1/2 potency and increasing by the 1/4 potency until the patient responds to treatment. There are several pediatric dosage ranges for children from birth to 12 years (see the prescribing information). The usual dosage in thyroid suppression therapy is based on the T4 dosage of 1.56 mcg/kg per day for 7 to 10 days. Some common side effects are sluggishness, fatigue, weight gain, and alopecia.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 3

C Thyrolar (liotrix)

Front 4

A synthetic analogue of the natural hormone vasopressin (antidiuretic hormone), this medication is used to treat diabetes insipidus, a condition in which patients experience excessive dilute urine output and thirst because water is not being concentrated in the kidneys. This brand of the medication is available as 0.1 mg and 0.2 mg tablets, a 10 mcg/spray intranasal solution, a 10 mcg/spray rhinal tube solution, and a 4 mcg/mg sterile solution for injection. The usual dosage is 0.1 to 1.2 mg orally daily in a single dose or multiple doses; 0.1 to 0.4 mL of the nasal spray or rhinal tube solution daily in a single dose or multiple doses; or 0.2 to 0.4 mcg subcutaneously or intravenously daily in two divided doses. Side effects associated with the injectable dose may include headache, flushing, nausea, and mild abdominal cramps. Patients using the nasal spray or rhinal tube have experienced headache, flushing, nasal congestion, rhinitis, and mild abdominal cramps. The tablet seems to be well tolerated.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 4

E DDAVP (desmopressin)

Front 5

This proton pump inhibitor is indicated for the long-term treatment of Zollinger-Ellison syndrome, a pathological hypersecretory condition that can result in tumors in the pancreas and duodenum and ulcers in the stomach and duodenum. It is available as 15 mg and 30 mg capsules, delayed-release orally disintegrating tablets, and delayed-release oral suspension granules (to be reconstituted with water). The dosage to treat Zollinger-Ellison syndrome is 60 mg taken by mouth once daily. Common adverse effects may include gastrointestinal pain, nausea, diarrhea, and constipation.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 5

D Prevacid (lansoprazole)

Front 6

Indicated as an adjunct to diet and exercise, this medication is indicated to help improve glycemic control in adults with type 2 diabetes mellitus. It is available as 25 mg, 50 mg, and 100 mg film-coated tablets. The usual starting dosage is 100 mg daily taken with or without food. The dosage is reduced in patients with renal insufficiency. The most common side effect of this drug when used as monotherapy is nasopharyngitis. In clinical trials, headache and upper respiratory infection occurred when this drug was used in combination therapy with pioglitazone and increased incidence of hypoglycemia when combined with metformin.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 6

H Januvia (sitagliptin)

Front 7

This medication is used as replacement therapy in conditions associated with a deficiency or absence of testosterone in men, such as idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency. It is available as a 200 mg/mL solution for injection. The dosage range is 50 to 400 mg injected IM deeply into the gluteal muscle every 2 to 4 weeks depending on the patient's response to the drug. Adverse effects may include gynecomastia, excessive frequency and duration of penile erections, and oligospermia.



A Tasmar (tolcapone)
B Decadron (dexamethazone)
C Thyrolar (liotrix)
D Prevacid (lansoprazole)
E DDAVP (desmopressin)
F Propecia (finasteride)
G Delatestryl (testosterone)
H Januvia (sitagliptin)
I Estrace (estradiol)
J Genotropin (Somatropin)

Back 7

G Delatestryl (testosterone)